Risk factor
Very poor trading liquidity
Profitability factor
Greatly undervalued vs peers
About
Dongwha Pharm Co., Ltd. is a South Korean entity primarily engaged in the production and distribution of pharmaceutical goods. The company's diverse offerings include prescription-only medications addressing a wide spectrum of health concerns such as digestive and infectious diseases, cardiovascular and metabolic disorders, inflammatory and respiratory conditions, musculoskeletal and neurological ailments, as well as dermatological and urological issues. Furthermore, they market an extensive selection of over-the-counter (OTC) remedies, covering categories like digestive aids, cold and flu treatments, anti-inflammatory and respiratory solutions, skin care, oral hygiene, liver support, nutritional supplements, tonics, topical pain relief, antihistamines, and remedies for sore throats, among other products. Beyond pharmaceuticals, Dongwha Pharm also ventures into quasi-drugs, health supplements, food and beverage items, and cosmetics. Established in 1897, the firm maintains its headquarters in Seoul, South Korea.
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap'